Benjamin E J, Virani S S, Callaway C W, et al. Heart disease and stroke statistics-2018 update: a report from the american heart association[J]. Circulation, 2018, 137(12): e67-e492.
[2]
Makhoul S, Dorschel S, Gambaryan S, et al. Feedback regulation of syk by protein kinase c in human platelets[J]. Int J Mol Sci, 2019, 21(1):176-182.
[3]
Schunke K J, Walton C B, Veal D R, et al. Protein kinase C binding protein 1 inhibits hypoxia-inducible factor-1 in the heart[J]. Cardiovasc Res, 2019, 115(8): 1332-1342.
[4]
Singh R K, Kumar S, Tomar M S, et al. Classical protein kinase C: a novel kinase target in breast cancer[J]. Clin Transl Oncol, 2019, 21(3): 259-267.
Sharp T E , Kubo H, Berretta R M, et al. Protein kinase C inhibition with ruboxistaurin increases contractility and reduces heart size in a swine model of heart failure with reduced ejection fraction[J]. JACC Basic Transl Sci, 2017, 2(6): 669-683.
[7]
Lange S, Gehmlich K, Lun A S, et al. MLP and CARP are linked to chronic PKC alpha signalling in dilated cardiomyopathy[J]. Nat Commun, 2016, 7(6): 12120.
[8]
Braun C, Parks X X, Qudsi H, et al. PKC betaII specifically regulates KCNQ1/KCNE1 channel membrane localization[J]. J Mol Cell Cardiol, 2019: 283-290.
[9]
Smyrnias I, Goodwin N, Wachten D, et al. Contractile responses to endothelin-1 are regulated by PKC phosphorylation of cardiac myosin binding protein-C in rat ventricular myocytes[J]. J Mol Cell Cardiol, 2018, 117: 1-18.
[10]
Lee S J, Kim S J, Lee H S, et al. PKC delta Mediates NF-kappa B inflammatory response and downregulates SIRT1 Expression in liver fibrosis[J]. Int J Mol Sci, 2019, 20(18): 4607.
[11]
Song M, Matkovich S J, Zhang Y, et al. Combined cardiomyocyte PKCdelta and PKC epsilon gene deletion uncovers their central role in restraining developmental and reactive heart growth[J]. Sci Signal, 2015, 8(373): 39.
[12]
Diaz J L, Macias L A, Alcala V F, et al. Redox signaling in ischemic postconditioning protection involves PKCepsilon and Erk1/2 pathways and converges indirectly in Nrf2 activation[J]. Cell Signal, 2019, 64(10): 109417.
[13]
Liu C, Li H, Zheng H, et al. CaSR activates PKC delta to induce cardiomyocyte apoptosis via ER stressassociated apoptotic pathways during ischemia/reperfusion[J]. Int J Mol Med, 2019, 44(3): 1117-1126.
[14]
Shou X, Wang B, Zhou R, et al. Baicalin suppresses hypoxia-reoxygenation-induced arterial endothelial cell apoptosis via suppressing PKCdelta/p53 signaling[J]. Med Sci Monit, 2017, 23: 6057-6063.
[15]
Lu Z, Ballou L M, Jiang Y P, et al. Restoration of defective L-type Ca2+ current in cardiac myocytes of type 2 diabetic db/db mice by Akt and PKC-iota[J]. J Cardiovasc Pharmacol, 2011, 58(4): 439-445.
[16]
Habets D D, Luiken J J, Ouwens M, et al. Involvement of atypical protein kinase C in the regulation of cardiac glucose and long-chain fatty acid uptake[J]. Front Physiol, 2012, 3: 361.
[17]
Ladage D, Tilemann L, Ishikawa K, et al. Inhibition of PKC alpha/beta with ruboxistaurin antagonizes heart failure in pigs after myocardial infarction injury[J]. Circ Res, 2011, 109(12): 1396-1400.
[18]
Wei L, Sun D, Yin Z, et al. A PKC-beta inhibitor protects against cardiac microvascular ischemia reperfusion injury in diabetic rats[J]. Apoptosis, 2010, 15(4): 488-498.
[19]
Zhong C, Wu Y, Chang H, et al. Effect of PKC inhibitor on experimental autoimmune myocarditis in Lewis rats[J]. Oncotarget, 2017, 8(33): 54187-54198.
[20]
Brennan S, Chen S, Makwana S, et al. A novel form of glycolytic metabolism-dependent cardioprotection revealed by PKC alpha and beta inhibition[J]. J Physiol, 2019, 597(17): 4481-4501.
[21]
Kunikawa S, Tanaka A, Takasuna Y, et al. A novel 2,4-diaminopyrimidine derivative as selective inhibitor of protein kinase C theta prevents allograft rejection in a rat heart transplant model[J]. Bioorg Med Chem, 2018, 26(20): 5499-5509.
[22]
Li Z, Abdullah C S, Jin Z Q .Inhibition of PKC-theta preserves cardiac function and reduces fibrosis in streptozotocin-induced diabetic cardiomyopathy[J]. Br J Pharmacol, 2014, 171(11): 2913-2924.
[23]
Fang Y H, Joo D J, Lim B J, et al. The effects of AEB071 (sotrastaurin) with tacrolimus on rat heterotopic cardiac allograft rejection and survival[J]. J Surg Res, 2011, 171(1): e133-137.
[24]
Kim E C, Lee M J, Shin S Y, et al. Phorbol 12-myristate 13-acetate enhances long-term potentiation in the hippocampus through activation of protein kinase cdelta and epsilon[J]. Korean J Physiol Pharmacol, 2013, 17(1): 51-56.
[25]
Miyaji Y, Walter S, Chen L, et al. Distribution of KAI-9803, a novel delta-protein kinase C inhibitor, after intravenous administration to rats[J]. Drug Metab Dispos, 2011, 39(10): 1946-1953.
[26]
Lincoff A M, Roe M, Aylward P, et al. Inhibition of delta-protein kinase C by delcasertib as an adjunct to primary percutaneous coronary intervention for acute anterior ST-segment elevation myocardial infarction: results of the protection ami randomized Controlled Trial[J]. Eur Heart J, 2014, 35(37): 2516-2523.
[27]
Kim H K, Cho S W, Heo H J, et al. A Novel atypical PKC-Iota inhibitor, echinochrome a, enhances cardiomyocyte differentiation from mouse embryonic stem cells[J]. Mar Drugs, 2018, 16(6):1-14.
Ravichandran V S, Patel H J, Pagani F D, et al. Cardiac contractile dysfunction and protein kinase C-mediated myofilament phosphorylation in disease and aging[J]. J Gen Physiol, 2019, 151(9): 1070-1080.
2020, Vol. 31 
